Longitudinal observational study of sporadic inclusion body myositis: Implications for clinical trials

A. Cortese, P. Machado, J. Morrow, L. Dewar, A. Hiscock, A. Miller, S. Brady, D. Hilton-Jones, M. Parton, M. G. Hanna

Research output: Contribution to journalArticlepeer-review

Abstract

Sporadic inclusion body myositis (IBM) is the most common acquired myopathy occurring in adults aged over 50. years. The aim of the study was to assess prospectively the clinical features and functional impact of sporadic inclusion body myositis (IBM). Clinical data, manual muscle testing (MMT), quantitative muscle testing (QMT) of quadriceps muscle and IBM functional rating scale (IBM-FRS) were collected according to a standardised protocol at baseline (n= 51) and one-year follow-up (n= 23). MMT, quadriceps QMT and IBM-FRS significantly declined after one year (by 5.2%, 27.9%, and 13.8%, respectively). QMT of the quadriceps muscle and IBM-FRS were the most sensitive measures of disease progression. After a median time of seven years of disease duration, 63% of patients had lost independent walking. Disease onset after 55. years of age, but not sex or treatment, is predictive of a shorter time to requirement of a walking stick. We detected no differences in disease presentation and progression between clinically and pathologically defined IBM patients. The study provides evidence that quadriceps QMT and IBM-FRS could prove helpful as outcome measures in future therapeutic trials in IBM.

Original languageEnglish
Pages (from-to)404-412
Number of pages9
JournalNeuromuscular Disorders
Volume23
Issue number5
DOIs
Publication statusPublished - May 2013

Keywords

  • Clinical trial
  • IBM-functional rating scale
  • Inclusion body myositis
  • Muscle disease
  • Myometry
  • Outcomes measures

ASJC Scopus subject areas

  • Clinical Neurology
  • Pediatrics, Perinatology, and Child Health
  • Genetics(clinical)
  • Neurology

Fingerprint

Dive into the research topics of 'Longitudinal observational study of sporadic inclusion body myositis: Implications for clinical trials'. Together they form a unique fingerprint.

Cite this